An early combination of concurrent chemoradiotherapy with immune checkpoint inhibitors for cervical cancer is superior to a late combination: a propensity-score matching analysis
In patients with cervical cancer treated with concurrent chemoradiotherapy, earlier immunotherapy improves survival and is equivalent in safety to ICIs late application.
Authors
- Panpan Zhao (ORCID: https://orcid.org/0000-0001-7579-0033)
- Ge Hong (ORCID: https://orcid.org/0000-0002-9278-3879)
- Jun-Jiao Gu
- Mingchuan Zhang (ORCID: https://orcid.org/0000-0002-2523-1089)
- Huiying Zhang (ORCID: https://orcid.org/0000-0002-5528-4712)
- Shuxia Cheng
- Yiming Ma (ORCID: https://orcid.org/0000-0001-5359-2802)
Institutions
- Zhengzhou University (CN)
- Henan University Huaihe Hospital and Huaihe Clinical Institute (CN)
- First Affiliated Hospital of Henan University of Science and Technology (CN)
- Henan Cancer Hospital (CN)
- First Affiliated Hospital of Henan University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-11-21
- DOI
- https://doi.org/10.3389/fonc.2024.1429176
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.85